-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are very limited data on intracranial hemorrhage (ICH) in patients receiving antithrombotic therapy after percutaneous coronary intervention (PCI)
.
Recently, the heart blood vessels published on the prestigious journal JAHA the areas of disease research article, the researchers used the Korean National Health Insurance database to determine the 219,274 who had no ICH patients undergoing PCI and surgery in the period 2007-2016, and analysis The non-traumatic ICH and all-cause mortality
.
During a median follow-up of 5.
6 years, 4171 patients developed ICH after PCI (total incidence rate was 3.
32 cases/1000 persons per year)
Cumulative mortality rate
The 1-year mortality rate after ICH was 38.
2%, and most deaths occurred within 30 days (n=999, mortality rate was 24.
2%)
.
No significant difference in the risk of death was observed between patients who developed ICH within and after PCI (adjusted hazard ratio 1.
New-onset ICH in stroke most often occurs early after PCI, and the risk of early death is high
Original source:
Pil Hyung Lee.
et al.
Intracranial Bleeding After Percutaneous Coronary Intervention: Time-Dependent Incidence, Predictors, and Impact on Mortality .
JAHA.
2021.
